TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of alkaptonuria with documented increased excretion of homogentisic acid~2. Willing and able to provide written, signed informed consent, or age appropriate written assent and written informed consent by a legally authorized representative after the study has been explained, prior to any research-related procedures.~3. Willing and able to be seen in the UCSD Clinical Center for Research or a satellite site for the study visits~4. Possession of insurance coverage for standard of care procedures, clearly stated in the consent forms~Exclusion Criteria:~1. Baseline tyrosine level above 250 mmol/mL~2. Baseline serum creatinine, creatine kinase, or transaminases 2x upper limit of normal~3. Baseline anemia or thrombocytopenia~4. Current participation in another investigational medication trial.~5. Pregnant or lactating women~6. Current keratopathy, contact use or uncontrolled glaucoma~7. History myocardial infarction or arrhythmia~8. History of pulmonary insufficiency~9. Psychiatric illness that may interfere with compliance or communication~10. Current malignancy or hypertension

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitisinone (Type: EXPERIMENTAL): all subjects will receive open-label nitisinone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice~* Be female and ≥18 and ≤75 years of age~* Be ambulatory and have ECOG performance stastus of ≤1~* Have histological confirmed breast cancer,and the speciman confirmed ER negative,PR negatiev, and HER-2 negative by immunochemistry technich of Fudan cancer hospital.~* Locally advanced or metastastic breast cancer who didn't receive first-line chemotherapy. No matter whether the patient has received anthracyclin or taxane treatment as neo-adjuvant or adjuvant treatment.~* Have at least one target lesion according to the RECIST criteria.~Exclusion criteria:~* Preganant or lactating women~* Advaced patient has received one or more chemotherapies~* Chemotherapy within four weeks preceding treatment start~* ECOG ≥ 2~* Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy~* Participation in any investigational drug study within 4 weeks preceeding treatment start~* Evidence of CNS metastasis~* History of another malignacy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer~* Abnormal laboratory values: hemoglobin \< 8. 0g/dl, neutrophil\< 1.5×109/L, platelet\< 100×109/L.~* serum creatine \> upper limit of normal (ULN)~* serum bilirubin \> ULN~* ALT and AST \>5×ULN~* AKP \>5×ULN~* Serious uncontrolled intercurrence infection~* Life expectancy of less than 3 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- gemcitabine and cisplatin (Type: EXPERIMENTAL): cisplatin and gemcitabine in the management of triple negative metastatic breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An fMRI Study Of Brain Response In Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women must have pain due to fibromyalgia~* Fibromyalgia must have been diagnosed at least 6 months prior to be eligible for this study~Exclusion Criteria:~* Patients with severe depression or other serious illness, who are left-handed, or who are pregnant or nursing are not eligible for this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin, then placebo (Type: EXPERIMENTAL): None
- Placebo, then pregabalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria Patients with rheumatoid arthritis (RA) who fulfill all of the following~1. Patients who are refractory to the treatment.~2. Patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted.~3. Patients without a history of or concurrent malignant tumors.~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological confirmation of relapsed or refractory acute myelogenous leukemia (AML) (by World Health Organization \[WHO\] classification) or untreated AML in participants who are unfit for intensive therapy.~2. Participant has an Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.~3. Participant must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula using ideal body mass (IBM) instead of mass.~4. Participant must have adequate liver function as demonstrated by:~   * aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN)\*~  * alanine aminotransferase (ALT) ≤ 3.0 × ULN\*~  * bilirubin ≤ 1.5 × ULN\* \*unless considered due to leukemic organ involvement. (Participants with Gilbert's Syndrome may have had a bilirubin \> 1.5 × ULN per discussion between the investigator and AbbVie medical monitor)~Exclusion Criteria:~1. Participant has received acute anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) prior to first dose of ABT-199.~2. Participant has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.~3. Participant has received potent Cytochrome P450, family 3, subfamily A (CYP3A) inducers (such as rifampin, carbamazepine, phenytoin and St. John's wort) and warfarin or requires the use of warfarin (due to potential drug-drug interactions that may potentially increase the exposure of warfarin and complications of this effect) within 7 days prior to the first dose of study drug.~4. Participant has received CYP3A inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within 5 days prior to the first dose of study drug.~5. Participant has a white blood cell count \> 25 x 10\^9/L.~6. Participant has acute promyelocytic leukemia (French-American-British Class M3 AML).~7. Participants with known active central nervous system (CNS) disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-199 (Type: EXPERIMENTAL): Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* EGFR- tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed locally advanced or metastatic NSCLC with activating EGFR-mutations~* Age \>= 18 years~* No diagnostic or therapeutic measures beyond routine clinical practice are required~* Patients for whom the treating physician has decided to initiate treatment with GIOTRIF~* Written informed consent prior inclusion~Exclusion criteria:~* Contraindication for Afatinib according to the Summary of Product characteristics~* Participation in another clinical study until 30 days after end of treatment~* Prior systemic chemotherapy (Neo-/adjuvant therapy is permitted)~* Previous treatment with an EGFR-tyrosine kinase inhibitor~* Patients not willing or not able to fill in quality of life questionnaires~* Patients with missing or impaired legal capacity~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sedation for Patients Undergoing Endoscopic Retrograde Cholangiopancreatography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18-65 yrs~2. ASA I \& II~Exclusion Criteria:~1. Age \< 18 yrs \& \> 65 yrs~2. ASA III \& IV patients~3. Chronic Liver Disease~4. Pregnant patients~5. Patients with a history of (H/O) Drug abuse~6. Patients refusing consent~7. H/o Acute kidney injury~8. H/o allergy to propofol / lidocaine/ NSAIDS~9. Post liver transplant patients~10. Patients with h/o egg allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: NO_INTERVENTION): The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
- Group B (Type: ACTIVE_COMPARATOR): The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
- Group C (Type: ACTIVE_COMPARATOR): Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure \& topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2~* Participant has relapsed/refractory disease (received at least one prior therapy)~* Diagnosis of CLL that meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines and:~  * has an indication for treatment according to the 2008 Modified IWCLL NCI-WG Guidelines~ * has clinically measurable disease (lymphocytosis \> 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)~ * with or without 17p deletion or TP53 mutation~ * may have been previously treated with a prior B-cell receptor inhibitor therapy~* Adequate bone marrow function~Exclusion Criteria:~* Participant has developed Richter's transformation or Prolymphocytic leukemia (PLL)~* Participant has previously received venetoclax~* History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:~  * adequately treated in situ carcinoma of the cervix uteri~ * adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin~ * previous malignancy confined and surgically resected (or treated with other modalities) with curative intent~* Active and uncontrolled autoimmune cytopenias (within 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP), despite low dose corticosteroids~* Prior allogeneic stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Venetoclax (Type: EXPERIMENTAL): Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and acceptance to provide written consent, fluent in English;~* Healthy subjects with no medical, psychiatric or current sleep disorders;~* Men or women between 18-75 years;~* Body Mass Index of ≥ 18 and ≤ 30 kg/m2.~Exclusion Criteria:~* Major surgery, trauma, illness or immobile for 3 or more days within the past month;~* Pregnancy or recent pregnancy (within 6 weeks);~* A positive test for drugs of abuse at the screening or evaluation visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Tasimelteon (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females, 18-65 years old.~* Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence, determined by the SCID.~* In the past 30 days, S used no less than $200-worth of cocaine and \>15 standard alcohol drinks (avg)/week with at least 1 day of 4 or more drinks, determined by the TLFB--adapted to collect daily cocaine use.~* Successful completion of alcohol detoxification, i.e.,~* 5 consecutive days of abstinence from cocaine and alcohol, via self-reports and negative urine toxicology screens.~* Lives a commutable distance to the TRC and agrees to follow-up visits.~* Understands and signs the consent.~Exclusion Criteria:~* Abstinent from cocaine or alcohol for 30 days prior to signing consent form. (S may have been institutionalized in the prior month and still be eligible if his/her cocaine and alcohol use that month met inclusion criteria.)~* Current DSM-IV diagnosis of any substance dependence other than cocaine, alcohol, nicotine, or cannabis determined by the SCID.~* Evidence of opiate use in the past 30 days, determined by self-report on the SCID or ASI, and/or by a urine drug screen that is positive for opiates at treatment entry.~* Current treatment with psychotropic medications (excluding short-term use of benzodiazepines for detoxification), including disulfiram.~* History of unstable or serious medical illness, including need for opioid analgesics.~* History of epilepsy or seizure disorder.~* Known severe physical or medical illnesses such as AIDS, active hepatitis, significant hepatocellular injury as evidenced by elevated bilirubin levels, or elevated levels over 4.5x normal of aspartate aminotransferase (AST), and serum glutamic-pyruvic transaminase (SGPT).~* Current severe psychiatric symptoms, e.g., psychosis, dementia, acute suicidal or homicidal ideation, mania or depression requiring antidepressant therapy, or which would make it unsafe for the patient to participate in the opinion of the primary investigators.~* Use of an investigational medication in the past 30 days.~* Female Ss who are pregnant, nursing, or not using a reliable method of contraception. \[Note: Criteria 4-10 will be assessed via the medical exam plus results from lab tests.\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nal + BRENDA
- 2 (Type: PLACEBO_COMPARATOR): Placebo + BRENDA
- 3 (Type: EXPERIMENTAL): Nal + CBT
- 4 (Type: PLACEBO_COMPARATOR): Placebo + CBT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic agents between the age of 30 to 70~3. Non-ST elevation Acute coronary syndrome with successful coronary stent implantation (with TIMI flow grade 3 after the procedure)~Exclusion Criteria:~1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients~2. No prior use of either ticagrelor or prasugrel within a month prior to randomization.~3. History of intracranial bleeding at any time~4. Active pathologic bleeding~5. Hemoglobin A1c \>9%~6. Type 1 diabetes~7. Decreased serum platelet level (\< 100,000/uL)~8. Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin~9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days~10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study~11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study~12. Involvement in the planning and/or conduct of the study~13. Left ventricular ejection fraction \< 40%~14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase \> twice the upper limit)~15. Gastrointestinal disorder such as Crohn's disease~16. Alcohol abuse~17. Steroid or hormone replacement therapy~18. Serum creatinine \> 2.0 mg/dL.~19. Prior history of CVA or stroke~20. Body weight \< 60 kg~21. Life expectancy less than a year~22. Known pregnancy, breast-feeding, or intend to become pregnant during the study period

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: ACTIVE_COMPARATOR): 180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
- Prasugrel (Type: ACTIVE_COMPARATOR): 60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory Hodgkin lymphoma who have previously received autologous stem cell transplant.~* Histologically confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.~* Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm as documented by spiral computed tomography.~* At US sites patients greater than or equal to 12 years of age may be enrolled. At non-US sites patients must be greater than or equal to 18 years of age.~Exclusion Criteria:~* Previous treatment with brentuximab vedotin.~* Previously received an allogeneic transplant.~* Congestive heart failure, Class III or IV, by the New York Heart Association criteria.~* History of another primary malignancy that has not been in remission for at least 3 years.~* Known cerebral/meningeal disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete